Genmab — November 2019
-
Konkurrent data til EnaV (bencemtinib + pembro) i NSCLS
-
-
God morgen.
-
GM. draft ASH Top 10 ( 859, 860, 862, 925 are Dara ) https://twitter.com/mtmdphd/status/1193260261160951808 https://www.myeloma.org/cure-blog/ash-top-10-2019-immune-therapies-again-dominate-news
https://twitter.com/szusmani/status/1192582644170665984 -
Dara + ATRA disappointing: Overall, this approach resulted in a modest prolongation of PFS. Patients with primary DARA-refractory disease did not benefit from the addition of ATRA. However, in patients with ≥PR on DARA monotherapy prior to progression, addition of ATRA and re-intensification of DARA was of marked clinical benefit with an additional 7.8 months of disease control. https://ash.confex.com/ash/2019/webprogram/Paper123383.html
-
Men deres patent har ikke så lang levetid mere.
https://www.biopharmadive.com/news/celgene-revlimid-patent-challenge-dr-reddys-ptab/548172/ -
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind